RxDoctor Payments Data

Kristel Sproles, APRN

Family · Covington, LANPI 1972266278

Payments from drug & device makers

$538in general payments, 2019–2025

Across 14 payments — averaging $38.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$294
  • Urogen Pharma, Inc.$108
  • Axonics, Inc.$37
  • 180 Medical, Inc.$27
  • Philips North America LLC$21
  • ABC Home Medical Supply, Inc.$18
  • plus $34 from 2 others

What the payments were for

  • Food & beverage$538100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teleflex LLC3$294
Urogen Pharma, Inc.4$108
Axonics, Inc.2$37
180 Medical, Inc.1$27
Philips North America LLC1$21
ABC Home Medical Supply, Inc.1$18
Pfizer1$18
Sumitomo Pharma America, Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$538 in reported general payments places this provider in the 50th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$25,033
Medicare patients
313
Services billed
418

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron212$126,596
GemtesaVibegron44$32,936
LinzessLinaclotide12$9,203
Tamsulosin Hcl637$8,180
Estradiol112$7,788
Oxybutynin Chloride ErOxybutynin Chloride266$4,457
Testosterone Cypionate87$3,363
Solifenacin Succinate85$2,756
Finasteride179$1,622
Methenamine Hippurate16$1,443
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst35$1,357
Fosfomycin Tromethamine11$1,132
Testosterone13$974
NitrofurantoinNitrofurantoin Macrocrystal41$875
Cephalexin136$806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$16$32,93644 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 3,610 family providers in Louisiana.

Other family in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →